Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.

Autor: Kytölä S; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Vänttinen IM; University of Helsinki, Helsinki, Finland., Ruokoranta T; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Partanen A; Kuopio University Hospital, Kuopio, Finland., Holopainen A; Kuopio University Hospital, Kuopio, Finland., Saad J; University of Helsinki, Helsinki, Finland., Kuusisto MEL; University of Oulu and Oulu University Hospital, Oulu, Finland, Oulu, Finland., Koskela S; Finland., Räty RK; HUS Helsinki University Central Hospital, Helsinki, Finland., Itälä-Remes M; Turku University Hospital, Turku, Finland., Västrik I; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Suvela M; University of Helsinki, Helsinki, Finland., Parsons AO; University of Helsinki, Helsinki, Finland., Porkka K; Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland., Wennerberg K; University of Copenhagen, Copenhagen N, Denmark., Heckman CA; University of Helsinki, Helsinki, Finland., Jalkanen T; Estimates Ltd, Turku, Finland., Huttunen T; Estimates Ltd, Turku, Finland., Ettala P MD; Turku University Hospital, Turku, Finland., Rimpiläinen J; Tampere University Hospital, Tampere, Finland., Siitonen T; Oulu University Hospital, Oulu, Finland., Pyörälä M; Kuopio University Hospital, Kuopio, Finland., Kuusanmäki H; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Kontro M; Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Publikováno v: Blood [Blood] 2024 Oct 02. Date of Electronic Publication: 2024 Oct 02.

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Autor: Kuusanmäki H; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark; Foundation for the Finnish Cancer Institute, Helsinki., Kytölä S; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki., Vänttinen I; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Ruokoranta T; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Ranta A; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Huuhtanen J; Hematology Research Unit, University of Helsinki, Helsinki., Suvela M; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Parsons A; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Holopainen A; Department of Medicine, Kuopio University Hospital, Kuopio., Partanen A; Department of Medicine, Kuopio University Hospital, Kuopio., Kuusisto MEL; Department of Medicine, Oulu University Hospital, Oulu, Finland; Department of Hematology, University of Oulu, Oulu., Koskela S; Department of Internal Medicine, Tampere University Hospital, Tampere., Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki., Itälä-Remes M; Department of Clinical Hematology, Turku University Hospital, Turku., Västrik I; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Dufva O; Hematology Research Unit, University of Helsinki, Helsinki., Siitonen S; Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital., Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Hematology Research Unit, University of Helsinki, Helsinki., Wennerberg K; Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen., Heckman CA; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki., Ettala P; Department of Clinical Hematology, Turku University Hospital, Turku., Pyörälä M; Department of Medicine, Kuopio University Hospital, Kuopio., Rimpiläinen J; Department of Internal Medicine, Tampere University Hospital, Tampere., Siitonen T; Department of Medicine, Oulu University Hospital, Oulu., Kontro M; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Foundation for the Finnish Cancer Institute, Helsinki, Finland; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki. mika.kontro@helsinki.fi.

Publikováno v: Haematologica [Haematologica] 2023 Jul 01; Vol. 108 (7), pp. 1768-1781. Date of Electronic Publication: 2023 Jul 01.

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.

Autor: Malani D; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Kumar A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Brück O; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Kontro M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland., Yadav B; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland., Hellesøy M; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.; Center for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway., Kuusanmäki H; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark., Dufva O; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland., Kankainen M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Eldfors S; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts, USA., Potdar S; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Saarela J; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Turunen L; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Parsons A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Västrik I; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Kivinen K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Saarela J; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Centre for Molecular Medicine Norway, NCMM, University of Oslo, Oslo, Norway., Räty R; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland., Lehto M; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland., Wolf M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Gjertsen BT; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.; Center for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway., Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Aittokallio T; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Institute for Cancer Research, Oslo University Hospital, and Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Norway., Wennerberg K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark., Heckman CA; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Kallioniemi O; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. kimmo.porkka@helsinki.fi olli.kallioniemi@scilifelab.se.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden., Porkka K; Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland. kimmo.porkka@helsinki.fi olli.kallioniemi@scilifelab.se.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Publikováno v: Cancer discovery [Cancer Discov] 2022 Feb; Vol. 12 (2), pp. 388-401. Date of Electronic Publication: 2021 Nov 17.

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.

Autor: Ka Iong Chan¹, Siyuan Zhang¹, Guodong Li¹, Yida Xu¹, Liao Cui², Yitao Wang¹, Huanxing Su¹ huanxingsu@um.edu.mo, Wen Tan³ tanwen@lzu.edu.cn, Zhangfeng Zhong¹ zfzhong@um.edu.mo

Publikováno v: Aging & Disease. Apr2024, Vol. 15 Issue 2, p640-697. 58p.

Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin.

Autor: Lymboussaki, A, Kaipainen, A, Hatva, E, Västrik, I, Jeskanen, L, Jalkanen, M, Werner, S, Stenbäck, F, Alitalo, R, Västrik, I, Stenbäck, F

Publikováno v: British Journal of Cancer; Jun1996, Vol. 73 Issue 11, p1347-1355, 9p